Jovana Despotović

Dr. Jovana Despotović

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

7 April 2021 in Cell Biochemistry and Biophysics
Verified
Journal Article
Closed access
PDF file
JDJovana Despotović
Jovana Despotović
SDSandra Dragicevic
Sandra Dragicevic
ANAleksandra Nikolic
Aleksandra Nikolic

25 May 2016 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
BJBojan Jevtić
Bojan Jevtić
NDNeda Djedović
Neda Djedović
SSSuzana Stanisavljevic
Suzana Stanisavljevic
JDJovana Despotović
Jovana Despotović
DMDjordje Miljkovic
Djordje Miljkovic
GTGordana Timotijević
Gordana Timotijević

1 October 2017 in Journal of Functional Foods
Verified
Journal Article
Closed access
BJBojan Jevtić
Bojan Jevtić
NDNeda Djedović
Neda Djedović
SSSuzana Stanisavljevic
Suzana Stanisavljevic
Uroš M GašićUroš M Gašić
Uroš M Gašić
DMDanijela Mišić
Danijela Mišić
GTGordana Timotijević
Gordana Timotijević

19 February 2026 in Cancer Control
Verified
Journal Article
Open access
JDJovana Despotović
Jovana Despotović
NNNeda Nikolic
Neda Nikolic
TBTamara Babić
Tamara Babić
MUMilena Ugrin
Milena Ugrin
ARAleksandra Đikić Rom
Aleksandra Đikić Rom
SDSandra Dragicevic
Sandra Dragicevic
Introduction: Early-onset colorectal cancer (EOCRC) is increasing worldwide, with Serbia showing a similar incidence compared to global trends. Precise mutation genotyping has gained importance following the recent approval of KRAS -specific inhibitors. Although KRAS , NRAS , and BRAF testing is routinely performed in Serbia, specific mutation subtypes in EOCRC patients have not yet been published. This retrospective cohort study aimed to investigate temporal trends in EOCRC incidence in Serbia and characterize the mutational profile of KRAS , NRAS , and BRAF in EOCRC patients. Methods: National cancer registry data from 2016 to 2022 were analyzed to assess EOCRC incidence trends. Molecular testing for KRAS , NRAS , and BRAF was performed on 681, 420, and 67 EOCRC patients, respectively, using qPCR-based diagnostic assays, complemented by Sanger sequencing on 54 cases to characterize KRAS exon 2 and BRAF V600E mutations. Results: Registry data revealed a consistent upward trend in EOCRC incidence, especially in the 45-49 years’ age group. In the qPCR-tested cohort, KRAS mutations were detected in 44.3% (302/681), NRAS in 6.4% (27/420), and BRAF in 8.9% (6/67). In the sequenced subset, KRAS mutations were found in 20.4%, including G12D (36.4%), G13D (27.3%), G12 C (18.1%), and G12S/G12 V (9.1%) variants. BRAF V600E was detected in 3.7%. Conclusions: We report a rise in EOCRC in Serbia, especially in ages 45-49, and recommend policy makers to lower the screening age to 45. We present the first detailed molecular profile of Serbian EOCRC and recommend that policy makers implement routine KRAS variant testing and ensure access to KRAS G12C-targeted therapies to improve personalized care.

17 July 2026 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
NĐNataša Đokić
Nataša Đokić
ABAnastasija Bubanja
Anastasija Bubanja
JKJelena Karanović
Jelena Karanović
JDJovana Despotović
Jovana Despotović
Background/Objectives: Long non-coding RNAs (lncRNAs) are important regulators of tumor biology through their interactions with DNA, proteins, and non-coding RNAs. Although ENST00000615487.1 (also known as CTD-2396E7.11/AC010503.4) has been associated with multiple malignancies, its biological role in colorectal cancer (CRC) remains poorly characterized. This study aimed to investigate the expression pattern, cellular and subcellular localization, and potential functional role of ENST00000615487.1 in CRC using integrated in vitro and in silico approaches. Methods: Molecular characteristics of the transcript were obtained with the CPC2 and RNA Analyzer 3 tools. Differential expression of ENST00000615487.1 across 10 tumor types was analyzed using the UCSC Xena Browser. Transcript expression was experimentally evaluated in normal, tumor, and fibroblastic colon cell lines by PCR, while subcellular localization was assessed through the lncATLAS, lncLocator, and iLoc-LncRNA tools, and experimentally confirmed by qRT-PCR. Single-cell RNA sequencing data from the GSE161277 dataset were analyzed to determine cell type-specific expression patterns. Potential interactions with DNA, miRNAs, and proteins were investigated using Fasim-LongTarget, miRDB, and AnnoLnc2, followed by functional enrichment analyses using STRING and Enrichr. Results: ENST00000615487.1 was identified as a structurally stable non-coding transcript with a highly organized secondary structure. Differential expression analysis demonstrated significant downregulation in CRC compared with that in normal colon tissue. Single-cell transcriptomic analysis revealed predominantly epithelial-specific expression. In silico and experimental analyses demonstrated predominant nuclear localization in normal colon cells, whereas cytoplasmic enrichment was observed in CRC cells. Functional analyses identified potential interactions with HIP1R, RPH3AL, specific miRNAs, and proteins involved in transcriptional regulation and RNA processing pathways, as well as functional connections with proteins involved in vesicular transport. Conclusions: ENST00000615487.1 is a structurally stable lncRNA exhibiting context-dependent expression and localization patterns in CRC, suggesting a potential shift from nuclear transcriptional regulation toward cytoplasmic post-transcriptional functions during colorectal carcinogenesis.